ClinConnect ClinConnect Logo
Search / Trial NCT06994325

Testing the CHAT Program for Patients With Heart Failure

Launched by WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY · May 20, 2025

Trial Information

Current as of July 09, 2025

Not yet recruiting

Keywords

H Fp Ef Chat Conversations Helpful For Awareness Of Illness Trajectory Effectiveness Implementation Trial Heart Failure With Preserved Ejection Fraction

ClinConnect Summary

This clinical trial is investigating a program called CHAT, designed to help people with a specific type of heart failure known as Heart Failure with Preserved Ejection Fraction (HFpEF). The researchers want to see if using videos for education and having a health coach can help patients understand and manage their condition better. They are looking to find out if this approach is acceptable and effective for patients.

To participate in the trial, individuals must be at least 60 years old and have a confirmed diagnosis of HFpEF, which means they have symptoms of heart failure and a specific measurement of heart function that is normal. However, people who have been referred to hospice care, completed advance directives, or have significant dementia or mental health issues that would affect their ability to give consent cannot join the study. The trial is not yet recruiting participants, but it aims to provide valuable insights into how education and support can improve care for those living with HFpEF.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Male or Female ≥ 60 years old
  • 2. Documentation of HFpEF according to clinical practice guidelines (signs \& symptoms of HF AND ejection fraction ≥50%)
  • Exclusion Criteria:
  • 1. Previously referred to hospice care
  • 2. Prior completion of advance directives
  • 3. Moderate-severe dementia or psychiatric disorder precluding informed consent.

About Weill Medical College Of Cornell University

Weill Medical College of Cornell University is a leading academic institution dedicated to advancing medical research and education. As a prominent sponsor of clinical trials, it focuses on innovative healthcare solutions and the development of new therapies across various medical disciplines. The institution is committed to fostering collaborative research efforts that enhance patient care and improve health outcomes. With a robust infrastructure and a team of experienced researchers and clinicians, Weill Cornell aims to translate scientific discoveries into practical applications, ensuring a strong emphasis on ethical standards and regulatory compliance throughout the clinical trial process.

Locations

New York, New York, United States

Patients applied

0 patients applied

Trial Officials

Parag Goyal, MD, MSc

Principal Investigator

Weill Medical College of Cornell University

Megan J Shen, PhD

Principal Investigator

Fred Hutchinson Cancer Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported